CN116134152A - 评估对冠状病毒感染产生严重反应的风险的方法 - Google Patents

评估对冠状病毒感染产生严重反应的风险的方法 Download PDF

Info

Publication number
CN116134152A
CN116134152A CN202180048201.7A CN202180048201A CN116134152A CN 116134152 A CN116134152 A CN 116134152A CN 202180048201 A CN202180048201 A CN 202180048201A CN 116134152 A CN116134152 A CN 116134152A
Authority
CN
China
Prior art keywords
subject
human
risk
beta coefficient
assigned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180048201.7A
Other languages
English (en)
Chinese (zh)
Inventor
吉莉安·休·迪特
尼古拉斯·马克·墨菲
理查德·奥尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Technologies Ltd
Original Assignee
Genetic Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901739A external-priority patent/AU2020901739A0/en
Application filed by Genetic Technologies Ltd filed Critical Genetic Technologies Ltd
Publication of CN116134152A publication Critical patent/CN116134152A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioethics (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202180048201.7A 2020-05-27 2021-05-26 评估对冠状病毒感染产生严重反应的风险的方法 Pending CN116134152A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2020901739 2020-05-27
AU2020901739A AU2020901739A0 (en) 2020-05-27 Methods of assessing risk of developing a severe response to Coronavirus infection
AU2020902052 2020-06-19
AU2020902052A AU2020902052A0 (en) 2020-06-19 Methods of assessing risk of developing a severe response to Coronavirus infection
AU2020903536 2020-09-30
AU2020903536A AU2020903536A0 (en) 2020-09-30 Methods of assessing risk of developing a severe response to coronavirus infection
AU2021900392A AU2021900392A0 (en) 2021-02-17 Methods of assessing risk of developing a severe response to Coronavirus infection
AU2021900392 2021-02-17
PCT/AU2021/050507 WO2021237292A1 (en) 2020-05-27 2021-05-26 Methods of assessing risk of developing a severe response to coronavirus infection

Publications (1)

Publication Number Publication Date
CN116134152A true CN116134152A (zh) 2023-05-16

Family

ID=78745661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180048201.7A Pending CN116134152A (zh) 2020-05-27 2021-05-26 评估对冠状病毒感染产生严重反应的风险的方法

Country Status (10)

Country Link
US (2) US11257569B1 (enExample)
EP (1) EP4158067A4 (enExample)
JP (1) JP2023527834A (enExample)
KR (1) KR20230019872A (enExample)
CN (1) CN116134152A (enExample)
AU (1) AU2021281702A1 (enExample)
CA (1) CA3179313A1 (enExample)
IL (1) IL298097A (enExample)
MX (1) MX2022014931A (enExample)
WO (1) WO2021237292A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117198517A (zh) * 2023-06-27 2023-12-08 安徽省立医院(中国科学技术大学附属第一医院) 基于机器学习的运动反应性评估和预测模型的建模方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023006518A (es) * 2020-12-03 2023-06-23 Regeneron Pharma Metodos de identificacion de sujetos que tienen un mayor riesgo de desarrollar una infeccion por coronavirus y su tratamiento.
US20230278029A1 (en) * 2022-03-01 2023-09-07 Dnanudge Limited Multiplex cartridge for detection of viral nucleic acids and human or animal snps
WO2023194369A1 (en) * 2022-04-08 2023-10-12 Fundació Institut Mar D'investigacions Mèdiques (Imim) Genetic markers for severe covid-19
PL248077B1 (pl) * 2023-10-10 2025-10-13 Biolab Genetic Spolka Z Ograniczona Odpowiedzialnoscia Sposób określania poziomu ryzyka ciężkiego przebiegu choroby COVID-19 u pacjenta
PL249351B1 (pl) * 2023-10-10 2026-03-30 Biolab Genetic Spółka Z Ograniczoną Odpowiedzialnością Zestaw i sposób do określania metodą łańcuchowej reakcji polimerazy układu alleli w locus rs143334143 oraz rs74956615
CN121458076B (zh) * 2026-01-08 2026-04-03 山西唐讯科技有限公司 输电线可视化监测数据智能分析和预警方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101186920A (zh) * 2003-03-24 2008-05-28 香港大学 对引起严重急性呼吸道综合症(sars)的人病毒的高通量诊断性试验
CN102712949A (zh) * 2009-06-01 2012-10-03 遗传技术有限公司 用于乳腺癌风险评估的方法
CN107002138A (zh) * 2014-09-30 2017-08-01 基因技术有限公司 用于评估发展乳腺癌风险的方法
CN110382712A (zh) * 2017-01-24 2019-10-25 基因技术有限公司 用于评估发展乳腺癌的风险的改进方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5714330A (en) 1994-04-04 1998-02-03 Lynx Therapeutics, Inc. DNA sequencing by stepwise ligation and cleavage
US5695934A (en) 1994-10-13 1997-12-09 Lynx Therapeutics, Inc. Massively parallel sequencing of sorted polynucleotides
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
JP4540754B2 (ja) 1996-06-04 2010-09-08 ユニバーシティ オブ ユタ リサーチ ファウンデーション Ｐｃｒ中のハイブリダイゼーションのモニタリング
US6485944B1 (en) 1997-10-10 2002-11-26 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
US6511803B1 (en) 1997-10-10 2003-01-28 President And Fellows Of Harvard College Replica amplification of nucleic acid arrays
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
AU7537200A (en) 1999-09-29 2001-04-30 Solexa Ltd. Polynucleotide sequencing
US6898531B2 (en) 2001-09-05 2005-05-24 Perlegen Sciences, Inc. Algorithms for selection of primer pairs
US20030108919A1 (en) 2001-09-05 2003-06-12 Perlegen Sciences, Inc. Methods for amplification of nucleic acids
CA2513899C (en) 2003-01-29 2013-03-26 454 Corporation Methods of amplifying and sequencing nucleic acids
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
EP2044221B1 (en) * 2006-07-21 2015-07-22 Epigenomics AG Methods and kit for analyses of methylation in colorectal cellular proliferative disorders
US10643951B2 (en) * 2017-07-14 2020-05-05 Taiwan Semiconductor Manufacturing Co., Ltd. Mini identification mark in die-less region of semiconductor wafer
WO2021016391A1 (en) * 2019-07-23 2021-01-28 The Broad Institute, Inc. Health data aggregation and outbreak modeling
US20210340636A1 (en) * 2020-03-31 2021-11-04 Diasorin S.P.A. Assays for the Detection of SARS-CoV-2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101186920A (zh) * 2003-03-24 2008-05-28 香港大学 对引起严重急性呼吸道综合症(sars)的人病毒的高通量诊断性试验
CN102712949A (zh) * 2009-06-01 2012-10-03 遗传技术有限公司 用于乳腺癌风险评估的方法
CN107002138A (zh) * 2014-09-30 2017-08-01 基因技术有限公司 用于评估发展乳腺癌风险的方法
CN110382712A (zh) * 2017-01-24 2019-10-25 基因技术有限公司 用于评估发展乳腺癌的风险的改进方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117198517A (zh) * 2023-06-27 2023-12-08 安徽省立医院(中国科学技术大学附属第一医院) 基于机器学习的运动反应性评估和预测模型的建模方法
CN117198517B (zh) * 2023-06-27 2024-04-30 安徽省立医院(中国科学技术大学附属第一医院) 基于机器学习的运动反应性评估和预测模型的建模方法

Also Published As

Publication number Publication date
MX2022014931A (es) 2023-01-30
AU2021281702A1 (en) 2023-01-05
JP2023527834A (ja) 2023-06-30
KR20230019872A (ko) 2023-02-09
CA3179313A1 (en) 2021-12-02
IL298097A (en) 2023-01-01
EP4158067A1 (en) 2023-04-05
US11257569B1 (en) 2022-02-22
WO2021237292A1 (en) 2021-12-02
US20220246242A1 (en) 2022-08-04
EP4158067A4 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
US11257569B1 (en) Methods of assessing risk of developing a severe response to coronavirus infection
JP6820838B2 (ja) 乳癌発症リスクを評価する方法
US20230383349A1 (en) Methods of assessing risk of developing a disease
CN111601901A (zh) 评估患乳腺癌的风险的方法
CN106119406B (zh) 多发性肉芽肿血管炎及微小动脉炎的基因分型诊断试剂盒及使用方法
JP7140707B2 (ja) 緑内障のリスクを判定する方法
JP2020174538A (ja) ２型糖尿病のリスクを判定する方法
JP2020178553A (ja) 妊娠高血圧症候群のリスクを判定する方法
JP2020178560A (ja) 動脈硬化のリスクを判定する方法
JP2020178589A (ja) リウマチのリスクを判定する方法
JP2020174641A (ja) 加齢黄斑変性のリスクを判定する方法
JP2020174639A (ja) 高血圧のリスクを判定する方法
JP2020178567A (ja) 脂肪肝のリスクを判定する方法
JP7161443B2 (ja) 尿管結石及び／又は腎結石のリスクを判定する方法
JP7165619B2 (ja) 慢性気管支炎のリスクを判定する方法
JP7099981B2 (ja) 痛風のリスクを判定する方法
CA3238945A1 (en) Breast cancer risk assessment
JP2020174638A (ja) 慢性中耳炎のリスクを判定する方法
JP2020178563A (ja) アレルギー性鼻炎のリスクを判定する方法
JP2020174625A (ja) 過食症のリスクを判定する方法
JP2020178558A (ja) 潰瘍性大腸炎のリスクを判定する方法
JP2020174622A (ja) 脂質異常症のリスクを判定する方法
JP2020174617A (ja) Ｂ型肝炎及び／又はｃ型肝炎のリスクを判定する方法
JP2020174642A (ja) 結核のリスクを判定する方法
JP2020178588A (ja) 膠原病のリスクを判定する方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230516